$ANKM
Ankam, Inc.

2024 Q2 Form 10-Q Financial Statement

#000178162924000011 Filed on April 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q4
Revenue $15.39K $9.760K $7.480K
YoY Change 45.17% 214.94%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $29.15K $47.42K -$93.28K
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization -$13.47K $36.16K $24.94K
YoY Change 418.2%
% of Gross Profit
Operating Expenses $87.21K $128.5K -$89.27K
YoY Change 15.55% 51.54%
Operating Profit
YoY Change
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $44.90K $44.90K -$179.2K
YoY Change 0.0% 0.0%
Pretax Income -$71.83K -$118.7K -$63.60K
YoY Change 10.72% -245.34%
Income Tax
% Of Pretax Income
Net Earnings -$71.83K -$118.7K -$63.60K
YoY Change 10.72% 45.34%
Net Earnings / Revenue -466.87% -1216.32% -850.27%
Basic Earnings Per Share -$0.02 -$0.03
Diluted Earnings Per Share -$0.02 -$0.03 -$0.01
COMMON SHARES
Basic Shares Outstanding 4.328M shares 4.328M shares 4.328M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.070K $710.00 $290.00
YoY Change
Cash & Equivalents $1.069K $707.00 $286.00
Short-Term Investments
Other Short-Term Assets $70.41K $72.28K $64.49K
YoY Change
Inventory
Prepaid Expenses $46.85K $36.01K $15.85K
Receivables $0.00 $21.39K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $71.48K $72.99K $86.17K
YoY Change -23.89% -42.23% -51.27%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $130.9K $144.0K $22.16K
YoY Change -48.73% -45.07% -91.77%
TOTAL ASSETS
Total Short-Term Assets $71.48K $72.99K $86.17K
Total Long-Term Assets $130.9K $144.0K $22.16K
Total Assets $202.3K $217.0K $108.3K
YoY Change -42.05% -44.15% -75.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $268.0K $244.0K $84.00K
YoY Change
Accrued Expenses $5.800K $23.53K $44.90K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $427.3K $365.6K $292.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $718.2K $661.0K $433.6K
YoY Change 32.54% 28.01% -11.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $718.2K $661.0K $433.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $718.2K $661.0K $433.6K
YoY Change 32.54% 28.01% -11.9%
SHAREHOLDERS EQUITY
Retained Earnings -$551.4K -$479.6K -$360.9K
YoY Change -341.55% -393.49% -541.53%
Common Stock $4.328K $4.328K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$515.8K -$444.0K -$325.3K
YoY Change
Total Liabilities & Shareholders Equity $202.3K $217.0K $108.3K
YoY Change -42.05% -44.15% -75.71%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q4
OPERATING ACTIVITIES
Net Income -$71.83K -$118.7K -$63.60K
YoY Change 10.72% 45.34%
Depreciation, Depletion And Amortization -$13.47K $36.16K $24.94K
YoY Change 418.2%
Cash From Operating Activities -$87.98K $84.85K -$320.4K
YoY Change -0.76%
INVESTING ACTIVITIES
Capital Expenditures $131.4K
YoY Change
Acquisitions -$158.0K
YoY Change
Other Investing Activities -$158.0K $241.4K
YoY Change
Cash From Investing Activities $26.64K -$158.0K $241.4K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 61.71K $73.61K 77.01K
YoY Change -13.09%
NET CHANGE
Cash From Operating Activities -87.98K $84.85K -320.4K
Cash From Investing Activities 26.64K -$158.0K 241.4K
Cash From Financing Activities 61.71K $73.61K 77.01K
Net Change In Cash 370.0 $421.00 -1.990K
YoY Change -152.56%
FREE CASH FLOW
Cash From Operating Activities -$87.98K $84.85K -$320.4K
Capital Expenditures $131.4K
Free Cash Flow -$219.4K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2024Q1 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
usd
CY2023 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
usd
CY2024Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
usd
CY2023Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
CY2023Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2024Q1 us-gaap Interest Paid
InterestPaid
usd
CY2023Q1 us-gaap Interest Paid
InterestPaid
usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
CY2024Q1 dei Contact Personnel Email Address
ContactPersonnelEmailAddress
[email protected]
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4327996 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
707 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36007 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
15847 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
36271 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
48643 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
72985 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
86166 usd
CY2024Q1 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
144037 usd
CY2023Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
22157 usd
CY2024Q1 us-gaap Assets
Assets
217022 usd
CY2023Q4 us-gaap Assets
Assets
108323 usd
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
244040 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
84000 usd
CY2024Q1 us-gaap Deferred Revenue
DeferredRevenue
27830 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
12700 usd
CY2024Q1 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
365636 usd
CY2023Q4 us-gaap Loans And Leases Receivable Related Parties
LoansAndLeasesReceivableRelatedParties
292026 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23532 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
44900 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
661038 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
433626 usd
CY2024Q1 us-gaap Liabilities
Liabilities
661038 usd
CY2023Q4 us-gaap Liabilities
Liabilities
433626 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4327996 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4327996 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4327996 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4327996 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
4328 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4328 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31262 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
31262 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-479606 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-360893 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-444016 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-325303 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
217022 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
108323 usd
CY2024Q1 us-gaap Revenues
Revenues
9760 usd
CY2023Q1 us-gaap Revenues
Revenues
3099 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
93 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
83 usd
CY2024Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
22000 usd
CY2023Q1 us-gaap Noninterest Expense Directors Fees
NoninterestExpenseDirectorsFees
18000 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
25322 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
14817 usd
CY2024Q1 us-gaap Other Expenses
OtherExpenses
44898 usd
CY2023Q1 us-gaap Other Expenses
OtherExpenses
44898 usd
CY2024Q1 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
36160 usd
CY2023Q1 us-gaap Depreciation And Amortization Discontinued Operations
DepreciationAndAmortizationDiscontinuedOperations
6978 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
128473 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
84776 usd
CY2024Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-118713 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-81677 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-118713 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81677 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4327996 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4327996 shares
CY2022Q4 us-gaap Shares Issued
SharesIssued
4327996 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-46146 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-81677 usd
CY2023Q1 us-gaap Shares Issued
SharesIssued
4327996 shares
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-127823 usd
CY2023Q4 us-gaap Shares Issued
SharesIssued
4327996 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-325303 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-118713 usd
CY2024Q1 us-gaap Shares Issued
SharesIssued
4327996 shares
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-444016 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-118713 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-81677 usd
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
36160 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6978 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21390 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-20160 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
4800 usd
CY2024Q1 ankm Increase Decrease In Right Of Use Assets And Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLiabilitiesNet
-8996 usd
CY2023Q1 ankm Increase Decrease In Right Of Use Assets And Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLiabilitiesNet
19698 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
160040 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-37899 usd
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
15130 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2599 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
84851 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85501 usd
CY2024Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-158040 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-158040 usd
CY2024Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
73610 usd
CY2023Q1 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
84700 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
73610 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
84700 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
421 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-801 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
286 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2277 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
707 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1476 usd
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
36271 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
36271 usd
CY2024Q1 us-gaap Basis Of Accounting
BasisOfAccounting
<p id="xdx_844_eus-gaap--BasisOfAccounting_zeLe4MZzoHMe" style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86B_zVLX0rIVoqE4">Interim Financial Statements</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes filed with the Securities and Exchange Commission (the “SEC”) for the year ended November 30, 2023.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 3pt 0; text-align: center">10<br/> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>ANKAM, INC.</b></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</b></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>As of February 29, 2024</b></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Unaudited)</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"> </p>
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_z1yw8bFOuYza" style="font: 12pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline"><span id="xdx_86B_zS93SaXdNiVi">Use of Estimates</span></span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2024Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
13419 usd
CY2023 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
53144 usd
CY2024Q1 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
36160 usd
CY2023Q1 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
6978 usd
CY2024Q1 us-gaap Debt Current
DebtCurrent
365636 usd
CY2023Q4 us-gaap Debt Current
DebtCurrent
292026 usd
CY2024Q1 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
479606 usd
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
360893 usd
CY2024Q1 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-479606 usd
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-360893 usd
CY2024Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
100717 usd
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
75787 usd
CY2024Q1 ankm Less
Less
-100717 usd
CY2023Q4 ankm Less
Less
-75787 usd

Files In Submission

Name View Source Status
0001781629-24-000011-index-headers.html Edgar Link pending
0001781629-24-000011-index.html Edgar Link pending
0001781629-24-000011.txt Edgar Link pending
0001781629-24-000011-xbrl.zip Edgar Link pending
ankm-20240229.xsd Edgar Link pending
ankm10q_29feb2024.htm Edgar Link pending
exh31.htm Edgar Link pending
exh32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
ankm-20240229_cal.xml Edgar Link unprocessable
ankm-20240229_def.xml Edgar Link unprocessable
ankm-20240229_lab.xml Edgar Link unprocessable
ankm-20240229_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ankm10q_29feb2024_htm.xml Edgar Link completed
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending